| Patberg M, Oniani T, Disse P, Peischard S, Vinnenberg L, Zobeiri M, Romanelli MN, Epping L, Wiendl H, Meuth SG, Hundehege P, Seebohm G, Budde T, Junker A. Optimized synthesis and pharmacological evaluation of HCN channel inhibitor EC18. Arch Pharm (Weinheim) 2023: e2200665. Abstract
|
| Schmidt S, Isaak A, Junker A. Spotlight on P2X7 Receptor PET Imaging: A Bright Target or a Failing Star?. Int J Mol Sci 2023;24Abstract
|
| Siutkina AI, Kalinina S, Liu R, Heitman LH, Junker A, Daniliuc CG, Kalinin DV. Microwave-Assisted Synthesis, Structure, and Preliminary Biological Evaluation of Novel 6-Methoxy-5,6-dihydro-5-azapurines. ACS Omega 2023;8: 14097-14112. Abstract
|
| Steiner ST, Maisuls I, Junker A, Fritz G, Faust A, Strassert CA. Concerning the photophysics of fluorophores towards tailored bioimaging compounds: a case study involving S100A9 inflammation markers. Photochem Photobiol Sci 2023;22: 2093-2104. Abstract
|
| Isaak A, Dobelmann C, Fusser FT, Erlitz KS, Koch O, Junker A. Unveiling the Structure-Activity Relationships at the Orthosteric Binding Site of P2X Ion Channels: The Route to Selectivity. J Med Chem 2022;65: 11291-11308. Abstract
|
| Lemmerhirt JP, Isaak A, Liu R, Kock M, Daniliuc CG, Jacobson KA, Heitman LH, Junker A. Development of Bicyclo[310]hexane-Based A3 Receptor Ligands: Closing the Gaps in the Structure-Affinity Relationships. Molecules 2022;27Abstract
|
| Oniani T, Vinnenberg L, Chaudhary R, Schreiber JA, Riske K, Williams B, Pape H-C, White JA, Junker A, Seebohm G, Meuth SG, Hundehege P, Budde T, Zobeiri M. Effects of Axonal Demyelination, Inflammatory Cytokines and Divalent Cation Chelators on Thalamic HCN Channels and Oscillatory Bursting. Int J Mol Sci 2022;23Abstract
|
| Scortichini M, Idris RM, Moschutz S, Keim A, Salmaso V, Dobelmann C, Oliva P, Losenkova K, Irjala H, Vaittinen S, Sandholm J, Yegutkin GG, Strater N, Junker A, Muller CE, Jacobson KA. Structure-Activity Relationship of 3-Methylcytidine-5'-alpha,beta-methylenediphosphates as CD73 Inhibitors. J Med Chem 2022Abstract
|
| Turgutalp B, Bhattarai P, Ercetin T, Luise C, Reis R, Gurdal EE, Isaak A, Biriken D, Dinter E, Sipahi H, Schepmann D, Junker A, Wunsch B, Sippl W, Gulcan HO, Kizil C, Yarim M. Discovery of Potent Cholinesterase Inhibition-Based Multi-Target-Directed Lead Compounds for Synaptoprotection in Alzheimer's Disease. J Med Chem 2022;65: 12292-12318. Abstract
|
| Oliva P, Scortichini M, Dobelmann C, Jain S, Gopinatth V, Toti KS, Phung NB, Junker A, Jacobson KA. Structure-activity relationships of pyrimidine nucleotides containing a 5'-alpha,beta-methylene diphosphonate at the P2Y6 receptor. Bioorg Med Chem Lett 2021;45: 128137. Abstract
|
| Patberg M, Isaak A, Fusser F, Ortiz Zacarias NV, Vinnenberg L, Schulte J, Michetti L, Grey L, van der Horst C, Hundehege P, Koch O, Heitman LH, Budde T, Junker A. Piperazine squaric acid diamides, a novel class of allosteric P2X7 receptor antagonists. Eur J Med Chem 2021;226: 113838. Abstract
|
| Silva DG, Feijens P-B, Hendrick R, Matheeussen A, Grey L, Caljon G, Maes L, Emery FS, Junker A. Development of Novel Isoindolone-Based Compounds against Trypanosoma brucei rhodesiense. ChemistryOpen 2021;10: 922-927. Abstract
|
| Silva DG, Junker A, de Melo SMG, Fumagalli F, Gillespie JR, Molasky N, Buckner FS, Matheeussen A, Caljon G, Maes L, Emery FS. Synthesis and Structure-Activity Relationships of Imidazopyridine/Pyrimidine- and Furopyridine-Based Anti-infective Agents against Trypanosomiases. ChemMedChem 2021;16: 966-975. Abstract
|
| Wagner S, de Moura Gatti F, Silva DG, Ortiz Zacarias NV, Zweemer AJM, Hermann S, De Maria M, Koch M, Weiss C, Schepmann D, Heitman LH, Tschammer N, Kopka K, Junker A. Development of the First Potential Nonpeptidic Positron Emission Tomography Tracer for the Imaging of CCR2 Receptors. ChemMedChem 2021;16: 640-645. Abstract
|
| Junker A, Renn C, Dobelmann C, Namasivayam V, Jain S, Losenkova K, Irjala H, Duca S, Balasubramanian R, Chakraborty S, Börgel F, Zimmermann H, Yegutkin G G, Müller C E, Jacobson K A. Structure-Activity Relationship of Purine and Pyrimidine Nucleotides as Ecto-5'-Nucleotidase (CD73) Inhibitors. J Med Chem 2019;11: 3677-3695. Abstract
|
| Liu Q, Junker A, Murakami K, Hu P. Automated Counting of Cancer Cells by Ensembling Deep Features. Cells 2019;8: 1019. Abstract
|
| Kokornaczyk AK, Thum S, Daniliuc CG, Junker A, Wünsch B. Molecular structure of a brominated 2-benzazepinone – a crucial intermediate in the synthesis of novel chemokine CCR2 receptor antagonists. Z. Naturforsch. B 2017;72: 421-424. Abstract
|
| Thum S, Kokornaczyk AK, Seki T, De Maria M, Ortiz Zacarias NV, de Vries H, Weiss C, Koch M, Schepmann D, Kitamura M, Tschammer N, Heitman LH, Junker A, Wunsch B. Synthesis and biological evaluation of chemokine receptor ligands with 2-benzazepine scaffold. Eur J Med Chem 2017;135: 401-413. Abstract
|
| Junker A, Kokornaczyk AK, Strunz AK, Wünsch B. Selective and Dual Targeting of CCR2 and CCR5 Receptors: A Current Overview. Top Med Chem 2015;14: 187-241. Abstract
|
| Junker A, Kokornaczyk AK, Zweemer AJM, Frehland B, Schepmann D, Yamaguchi J, Itami K, Faust A, Hermann S, Wagner S, Schafers M, Koch M, Weiss C, Heitman LH, Kopka K, Wunsch B. Synthesis, binding affinity and structure-activity relationships of novel, selective and dual targeting CCR2 and CCR5 receptor antagonists. Org Biomol Chem 2015;13: 2407-2422. Abstract
|
| Strunz AK, Zweemer AJM, Weiss C, Schepmann D, Junker A, Heitman LH, Koch M, Wunsch B. Synthesis and biological evaluation of spirocyclic antagonists of CCR2 (chemokine CC receptor subtype 2). Bioorg Med Chem 2015;23: 4034-4049. Abstract
|
